Richard Scott Struthers - 01 Mar 2023 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
President & CEO, Director
Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
01 Mar 2023
Transactions value $
$0
Form type
4
Filing time
03 Mar 2023, 15:31:33 UTC
Previous filing
14 Oct 2022
Next filing
17 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Award $0 +61.7K +90% $0.00 130K 01 Mar 2023 Direct F1
holding CRNX Common Stock 1K 01 Mar 2023 By Spouse
holding CRNX Common Stock 731K 01 Mar 2023 By Family Trust 1
holding CRNX Common Stock 90K 01 Mar 2023 By Family Trust 2
holding CRNX Common Stock 90K 01 Mar 2023 By Family Trust 3
holding CRNX Common Stock 90K 01 Mar 2023 By Family Trust 4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Common Stock (right to buy) Award $0 +288K $0.00 288K 01 Mar 2023 Common Stock 288K $19.64 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2024.
F2 The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 1, 2023.